Aclaris Therapeutics
ACRS
110 hedge funds and large institutions have $1.02B invested in Aclaris Therapeutics in 2022 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 37 increasing their positions, 43 reducing their positions, and 31 closing their positions.
432% more call options, than puts
Call options by funds: $1.15M | Put options by funds: $217K
26% more capital invested
Capital invested by funds: $815M → $1.02B (+$208M)
13% more funds holding in top 10
Funds holding in top 10: 8 → 9 (+1)
5.32% more ownership
Funds ownership: 91.53% → 96.85% (+5.3%)
14% less repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 43
17% less funds holding
Funds holding: 133 → 110 (-23)
65% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 31
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$31.1M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$24.8M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$22.3M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$16.5M |
| 5 |
O
OrbiMed
New York
|
+$8.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$13.1M |
| 2 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
-$6.82M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$6.48M |
| 4 |
FM
Frazier Management
Seattle,
Washington
|
-$5.94M |
| 5 |
PA
Perceptive Advisors
New York
|
-$5.43M |
ACRS Hedge Fund Activity: Q1 2022 in Review
110 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q1 2022, worth a combined $1.02B — up 26% from $815M a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of ACRS and 11 opened new positions — a net loss of 20 holders — while 43 trimmed existing stakes and 37 added.
The largest buyer was BVF Inc, adding an estimated $31.1M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $13.1M sold.
- 110 institutional investors held Aclaris Therapeutics (ACRS) as of Q1 2022, down from 133 in Q4 2021.
- Funds reported $1.02B of Aclaris Therapeutics stock for Q1 2022, up 26% quarter-over-quarter.
- 11 funds opened new Aclaris Therapeutics positions in Q1 2022 and 31 closed out, a net change of -20 holders.
- The largest Aclaris Therapeutics buyer in Q1 2022 was BVF Inc, an estimated $31.1M added.
- The largest Aclaris Therapeutics seller in Q1 2022 was Cormorant Asset Management, an estimated $13.1M sold.
Based on aggregated 13F filings for Q1 2022.